Journal
MICROORGANISMS
Volume 9, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms9122531
Keywords
acute toxoplasmosis; chronic toxoplasmosis; parasite therapeutic targets; neuropathies; antiparasitic drugs; immunomodulatory drugs
Categories
Funding
- Medical Practice Plan (Faculty of Medicine, American University of Beirut)
- American University of Beirut
- Centre National de Recherche Scientifique Libanais (AUB-CNRS-L GRP)
Ask authors/readers for more resources
Toxoplasmosis is a prevalent disease caused by a parasite that can have serious health consequences for fetuses, newborns, and immunocompromised patients. Current drugs mainly target acute toxoplasmosis, with limited effect on the chronic form. Research is focused on discovering new treatment methods to lessen the burden of the disease.
Toxoplasmosis is a prevalent disease affecting a wide range of hosts including approximately one-third of the human population. It is caused by the sporozoan parasite Toxoplasma gondii (T. gondii), which instigates a range of symptoms, manifesting as acute and chronic forms and varying from ocular to deleterious congenital or neuro-toxoplasmosis. Toxoplasmosis may cause serious health problems in fetuses, newborns, and immunocompromised patients. Recently, associations between toxoplasmosis and various neuropathies and different types of cancer were documented. In the veterinary sector, toxoplasmosis results in recurring abortions, leading to significant economic losses. Treatment of toxoplasmosis remains intricate and encompasses general antiparasitic and antibacterial drugs. The efficacy of these drugs is hindered by intolerance, side effects, and emergence of parasite resistance. Furthermore, all currently used drugs in the clinic target acute toxoplasmosis, with no or little effect on the chronic form. In this review, we will provide a comprehensive overview on the currently used and emergent drugs and their respective parasitic targets to combat toxoplasmosis. We will also abridge the repurposing of certain drugs, their targets, and highlight future druggable targets to enhance the therapeutic efficacy against toxoplasmosis, hence lessening its burden and potentially alleviating the complications of its associated diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available